shutterstock_1463056853.jpg

MEDSIR-LED CLINICAL TRIALS UNITE SCIENTIFIC EXCELLENCE, PATIENT FOCUS AND STRATEGIC THINKING. MEDSIR MANAGEMENT MODEL ENSURES SPEED, RELIABILITY AND THE STREAMLINING OF CLINICAL DEVELOPMENT PLANS.

SMART STUDY DESIGNS FOR STRATEGIC CLINICAL TRIALS

WE STRIVE TO IMPROVE THE LIVES OF ALL PATIENTS WITH CANCER

Our projects

The MEDSIR concept of providing a platform to facilitate the development of ideas into strategic clinical study protocols is becoming more diverse, incorporating not only new tumor types, but also modern and innovative trial designs such as umbrella and multi-tumor basket trials.

Working on a new clinical project with the expectation that it will help many patients is exhilarating for
MEDSIR, a job well done means results that have the potential to change clinical practice. Here you will find our comprehensive project portfolio.

Please contact us for further information.


“LET´S CONVERT YOUR RESEARCH IDEA INTO A BRIGHTER FUTURE FOR CANCER PATIENTS”

MEDSIR'S CLINICAL STUDIES 

Our projects
arrow&v
arrow&v
arrow&v

ABIGAIL

BREAST

Abemaciclib with endocrine therapy ± paclitaxel in aggressive ER+/HER2- advanced breast cancer

BARBICAN

BREAST

Evaluation of ipatasertib added to combination of neoadjuvant chemotherapy and atezolizumab in women with TNBC

COPÉRNICO

COVID-19

Tocilizumab with pembrolizumab for treatment of COVID-19 pneumonia in patients unresponsive to standard care

KELLY

BREAST

Pembrolizumab and eribulin for HR+/HER- metastatic breast cancer previously treated with antracyclines and taxanes

MERIBEL

BREAST

First Line Eribulin monotherapy In HER2- Metastatic Breast Cancer

OPHELIA

BREAST

Olaparib plus Trastuzumab for HER2+, BRCA Mutated or HRD Advanced Breast Cancer

PATHFINDER

BREAST

Ipatasertib with non-taxane chemotherapy for taxane-pretreated unresectable locally advanced or metastatic TNBC

PHERGain

BREAST

Chemotherapy-free trastuzumab and pertuzumab in HER2-positive breast cancer: A FDG-PET response-adapted strategy

PQR309-007

BREAST

PQR309 and eribulin for locally advanced or metastatic HER- and TNBC

TRASTYVERE

BREAST

Clinical benefit of trastuzumab with lapatinib in HER2+ breast cancer previously treated with trastuzumab and/or lapatinib

ASUNCTIS

COVID-19

Open label trial of Asunercept for severe COVID-19 disease

BIOPER

BREAST

Molecular Mechanisms of Resistance and Sensitivity to Palbociclib Re-challenge in ER+ metastatic breast cancer

DEBBRAH

BREAST

Trastuzumab deruxtecan in HER2+ advance breast cancer with brain mets and/or leptomeningeal carcinomatosis

LINGain

BREAST

Sub-study of predictive immunogenicity biomakers for target therapy in HER2+ early breast cancer

METALLICA

BREAST

Metformin to prevent hyperglycemia in HR+/HER- PI3KCA-mutated advanced breast cancer patients treated with alpelisib and endocrine therapy

ORPHEUS

PENIS

Phase II Study of the Efficacy of INCMGA00012 in Penile Squamous Cell Carcinoma

PECATI

THYMIC

Phase II study of the combination of Pembrolizumab and Lenvatinib in pre-treated thymic carcinoma

POEM

ENDOMETRIUM

Identification of endometrial cacinoma biomarkers associated with a short term exposure to temsirolimus

REVERT

BREAST

Eribulin monotherapy or eribulin plus endocrine therapy in locally-recurrent or metastatic breast cancer patients after progression on endocrine therapy

ZZFIRST

PROSTATE

Enzalutamide Plus Talazoparib for the Treatment of Hormone Sensitive Prostate Cancer

ATractiB

BREAST

First-line atezolizumab with paclitaxel and bevacizumab for advanced or metastatic TNBC

BRIDGE

LUNG

Durvalumab and chemotherapy induction followed by durvalumab and radiotherapy in large volume stage III NSCLC

DxCARTES

BREAST

Neoadjuvant Letrozole and Palbociclib in Patients With Stage II-IIIB HR+, HER2- Breast Cancer

LUPER

LUNG

Lurbinectedin with Pembrolizumab in relaspsed small cell lung cancer

NOBROLA

BREAST

A Two-stage Simon Design Phase II Study of Single Agent Olaparib for Non-BRCA MBC Patients With HRD

PALMIRA

BREAST

Palbociclib with second-line endocrine therapy for HR+/HER2- Advanced Breast Cancer patients who had a clinical benefit during first-line palbociclib-based treatment

PHENOMENAL

BREAST

Nal-iri for progressing brain mets in patients with HER2- breast cancer

POLEN

ENDOMETRIUM

Biomarker changes associated to short exposure to olaparib as potential predictors in Endometrial Carcinoma

SLLIP

LUNG

Spanish Lung Liquid vs. Invasive biopsy Program

transFAL

BREAST

Sub-study of predictive biomarkers for palbociclib and endocrine therapy in ER+/HER2- advanced breast cancer

AZENT

Lung Cancer

Osimertinib in First-line Locally Advanced or Metastatic NSCLC Patients With EGFR and EGFR T790M

CAILA

BREAST

CB-103 plus NSAI and letrozole or anastrozole in luminal advanced breast cancer

EXCAAPE

PROSTATE

Evaluation of Rad-223 Activity in Asymptomatic Patients With mCRPC While on Abiraterone or Enzalutamide Besides AR-V7 Status

LUZERN

BREAST

Niraparib plus Aromatase Inhibitors for Luminal-like and gBRCA or HRD-positive Metastatic Breast Cancer

NSABP FB-7

BREAST

Neoadjuvant therapy with weekly (1) paclitaxel and neratinib, or (2) trastuzumab and paclitaxel, or (3) neratinib, trastuzumab, and paclitaxel, followed by doxorubicin and cyclophosphamide for postoperative locally...

PARSIFAL

BREAST

Palbociclib with fulvestrant or letrozole for HER-, ER+ metastatic breast cancer

PHERGAIN-2

BREAST

Trastuzumab, pertuzumab and TDM1 for HER2+ early breast cancer

POLTER

BREAST

Optimization of balixafortide with nab-paclitaxel or eribulin for HER2- advanced breast cancer

THELMA

BREAST

Trastuzumab emtansine (TDM1) with non pegylated liposomal doxorubicin in HER2+ metastic breast cancer

PUBLICATIONS

Publications

THE ULTIMATE GOAL OF MEDSIR PROJECTS IS THE PUBLICATION OF ITS STUDY RESULTS, WHETHER IN PEER-REVIEWED JOURNALS OR AT A NUMBER OF NATIONAL AND INTERNATIONAL CONFERENCES IN THE FORM OF ABSTRACTS, POSTERS, OR ORAL PRESENTATIONS.

YEAR

CONGRESS

ABSTRACT (Posters, presentations, etc.)

PROJECT

EXCAAPE

a multicenter, single-arm, open-label, non-controlled phase IIa clinical trial for patients with metastatic castration-resistant prostate cancer (mCRPC) with asymptomatic progression while on abiraterone acetate or enzalutamide.

download.png

ESMO

2020

KELLY

A phase II study of pembrolizumab and eribulin in patients with HRpositive/HER2-negative metastatic breast cancer previously treated with anthracyclines and taxanes.

download.png

SABCS

2019

REVERT

A multicenter, randomized, phase II trial evaluating the efficacy of eribulin monotherapy and eribulin plus endocrine therapy in locally-recurrent or metastatic breast cancer patients after progression on endocrine therapy (REVERT).

download.png

SABCS

2019

TRANSFAL

Prospective evaluation of predictive/prognostic biomarkers for palbociclib and endocrine therapy in ER positive HER2 negative advanced metastatic breast cancer within the PARSIFAL clinical trial.

download.png

SABCS

2019

PALMIRA

PALbociclib rechallenge in horMone receptor-posItive/HER2-negative Advanced breast cancer.

download.png

ESMO

2019

Other MEDSIR related articles

home_fondo_cuadritos2.jpg
"
WE TURN THE BEST CLINICAL RESEARCH IDEAS INTO A BRIGHTER FUTURE FOR CANCER PATIENTS.